In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…
HOME > Reimbursement Listing in 2018-2019
Reimbursement Listing in 2018-2019
-
Chuikyo OKs Listing of Astellas’ AML Med, Lilly’s Verzenio and More on Nov. 20
November 14, 2018
-
Maviret Faces 25% Price Slash in Quarterly Review
November 14, 2018
-
Despite Being 4th in ALK Class, Lorbrena Qualifies for PMP as It Gets 5% Pricing Premium
November 14, 2018
-
Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
-
Chuikyo OKs Pricing of Entyvio, Imfinzi, Gazyva and More; Listing on Aug. 29
August 22, 2018
-
Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
-
Chuikyo Rep Frowns on Low Manufacturing Cost Disclosure, Says New Rule Might Need Revisiting
May 17, 2018
-
Chuikyo Reps Chide Delay in Parmodia Listing
May 17, 2018
-
Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
May 17, 2018
-
Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
-
Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
ページ
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…